WebJan 9, 2024 · As part of the transaction, Ipsen will also acquire Albireo's clinical stage asset A3907, in development for adult cholestatic liver disease, which could complement Ipsen's existing development... WebJan 9, 2024 · In addition to Bylvay and A3907, Albireo's pipeline includes A2342, an oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor being evaluated for viral and cholestatic diseases, which is moving ahead in investigational new drug (IND)-enabling trials. Financial highlights
A3907, a systemic ASBT inhibitor, improves cholestasis in mice …
WebJan 9, 2024 · French biopharma Ipsen has agreed to acquire Boston-based Albireo Pharma for $42 per share, plus a contingent value right of $10 per share, the two companies announced Monday. The CVR is payable upon FDA approval of Albireo’s Bylvay as a treatment for biliary atresia, a rare liver disease. WebA3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans Hepatology. 2024 Apr 3. doi: 10.1097/HEP.0000000000000376. Online ahead of print. seattle ums
Albireo Announces Positive Topline Data from Phase 1 …
WebOct 4, 2024 · Operating as Envoy Air 3907. PNS Pensacola, FL. DFW Dallas-Fort Worth, TX. left Gate 5 Pensacola Intl - PNS. arrived at Gate B47 Dallas-Fort Worth Intl - DFW. … WebNov 2, 2024 · Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 … WebFeb 1, 2024 · Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the... seattle umhlanga